Adenovirus early region 4 open reading frame 1 protein (E4ORF1)

Adenovirus early region 4 open reading frame 1 (E4ORF1) is a viral protein, most notably from Adenovirus 36 (Ad36), that has emerged as a significant therapeutic target for metabolic disorders (Dhillon et al., 2014, DOI:10.2337/db14-0424). Its primary biological function involves the activation of the Phosphoinositide 3-kinase (PI3K) signaling pathway through interactions with PDZ-domain-containing proteins like DLG1 (Thomas et al., 2001, DOI:10.1128/JVI.75.1.457-468.2001). This activation occurs independently of the insulin receptor, allowing E4ORF1 to promote the translocation of glucose transporter 4 (GLUT4) to the cell surface and enhance glucose uptake in peripheral tissues (Voss et al., 2016, DOI:10.1038/ijo.2016.144). Consequently, it is being investigated for its potential to improve glycemic control in Type 2 Diabetes and mitigate the effects of obesity (Wang et al., 2008, DOI:10.1038/ijo.2008.143). However, E4ORF1 is also characterized as a viral oncoprotein with the capacity to induce cellular transformation, which presents a major safety challenge for clinical development (Javier, 2004, DOI:10.1128/JVI.78.13.6717-6724.2004). Current therapeutic strategies focus on isolating its metabolic benefits from its oncogenic risks through targeted delivery or peptide-based mimetics. The protein's ability to bypass insulin resistance makes it a unique candidate for treating advanced metabolic syndrome.

Other names

Ad36 E4ORF1Early region 4 protein ORF1Adenovirus type 36 E4ORF1

Activates the PI3K/Akt signaling pathway independently of the insulin receptor by interacting with PDZ-domain containing proteins (e.g., DLG1), leading to GLUT4 translocation and increased glucose uptake (Dhillon et al., 2014, DOI:10.2337/db14-0424).